Abstract
This study was conducted to determine the efficacy and safety of irinotecan (CPT-11) as second-line therapy in patients with advanced cervical carcinoma. Sixteen patients with platinum-resistant squamous cell carcinoma were treated with CPT-11 as second-line therapy. CPT-11 was administered in repeated 6-week cycles comprised of the administration of CPT-11 once weekly for 4 weeks, followed by a 2-week rest. The starting dose of CPT-11 was 125 mg/M2 given intravenously over 90 minutes; subsequent doses were adjusted based on individual patient tolerance. The median age of the patients was 43 years (range, 27-69 years). Three patients had a baseline Eastern Cooperative Oncology Group performance score (PS) of 0, 8 had a PS of 1, and 5 had a PS of 2. All patients had received cisplatin-based chemotherapy and 13 of 16 patients (81.3%) had been treated with prior pelvic/abdominal radiation therapy. Fourteen patients were evaluable for response. There were no objective responses although subjective decreases in symptoms were observed in some patients. Grade 3 to 4 toxicities included diarrhea in three patients, nausea and emesis in one patient, leukopenia in six patients, and neutropenia in five patients. Eighteen of 25 cycles requi...Continue Reading
References
Aug 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·N MasudaM Takada
Jan 1, 1990·Advances in Pharmacology·E SchneiderL F Liu
Nov 24, 1989·Science·B C GiovanellaM Potmesil
May 1, 1988·Biochemical Pharmacology·Y H HsiangL F Liu
Jan 1, 1988·Cancer Chemotherapy and Pharmacology·T MatsuzakiT Tsuruo
Aug 1, 1985·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P BonomiF J Major
Nov 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M L RothenbergG I Rodriguez
Jan 1, 1996·CA: a Cancer Journal for Clinicians·S L ParkerP A Wingo
Feb 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C F VerschraegenJ J Kavanagh
Citations
Jul 6, 2014·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Perry W GrigsbyGiuseppe Del Priore
Sep 24, 2014·Radiation Oncology·Zhijie LiShiyu Han
Feb 25, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·N KatsumataK Ochiai
Sep 18, 2012·Spectrochimica Acta. Part A, Molecular and Biomolecular Spectroscopy·P Chinna BabuE Murano
Jun 26, 2012·Cancer Treatment Reviews·Giannis MountziosChristos A Papadimitriou
Mar 17, 2010·Gynecologic Oncology·M FabbroJ-E Kurtz
Jul 29, 2008·Cancer Treatment Reviews·D PectasidesE Pectasides
Aug 25, 2004·Cancer Treatment Reviews·Andrea AlimontiMario Di Palma
Jun 1, 2000·Gynecologic Oncology·M A BookmanW A Andersen
Jul 10, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Harry J Long
Aug 5, 2004·British Journal of Cancer·H TsudaS Negoro
Dec 25, 2007·Cancer Gene Therapy·J UchinoY Nakanishi
Jun 11, 2005·Pharmaceutical Research·Zeping HuShufeng Zhou
Sep 16, 1999·British Journal of Cancer·T SugiyamaN Umesaki
Feb 13, 2001·The Oncologist·M L Rothenberg
Oct 12, 2000·Medical and Pediatric Oncology·C Rodriguez-GalindoP J Houghton
Apr 6, 2013·Cancer Chemotherapy and Pharmacology·Mayu YunokawaYasuhiro Fujiwara
Oct 3, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C LhomméB Chevallier
Jan 25, 2006·Molecular Cancer Therapeutics·Tadashi IkegamiBernard Bouscarel
Jun 12, 2001·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P M Sanz-AltamiraL B Saltz